BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in EuropeBy Nasdaq OMXJan 26, 2017, 3:51 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
